Welcome to our dedicated page for BIO-PATH HOLDINGS news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on BIO-PATH HOLDINGS stock.
Bio-Path Holdings develops targeted nucleic acid drug candidates using its DNAbilize® liposomal delivery and antisense RNAi nanoparticle technology. Its disclosed pipeline includes prexigebersen (BP1001), which targets Grb2 for blood cancers; BP1001-A, a modified prexigebersen candidate studied in solid tumors and metabolic disease models; BP1002, which targets Bcl-2 for blood cancers and solid tumors; and a STAT3 antisense program.
Company news commonly covers clinical and preclinical program updates, obesity and Type 2 diabetes research, acute myeloid leukemia and other oncology studies, patent grants tied to DNAbilize®, financial results, investor presentations, and corporate or operational updates affecting the biotechnology portfolio.
Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced that CEO Peter Nielsen will present at the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10, 2022, at 7:00 a.m. ET. The pre-recorded presentation will be accessible via an audio webcast on Bio-Path's website for 90 days post-event. Bio-Path focuses on developing targeted cancer drugs using its proprietary DNAbilize® RNAi technology. Its lead candidate, prexigebersen (BP1001), is currently in Phase 2 trials for blood cancers, while other products are also in development for various cancers.
Bio-Path Holdings (NASDAQ: BPTH) recently showcased preliminary data at the 2021 ASH Annual Meeting, demonstrating the safety and efficacy of prexigebersen in high-risk AML patients. The Phase 2 study involved patients treated with prexigebersen combined with decitabine and venetoclax. Key outcomes indicated that 50% of patients receiving the prexigebersen + decitabine regimen achieved responses, while 67% of those on the combination therapy with venetoclax reached complete remission. These results are promising for a challenging patient population.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) reported its Q3 2021 financial results, achieving a net loss of $2.1 million, or $0.29 per share, compared to a $3.0 million loss or $0.80 per share in Q3 2020. The company saw a decrease in R&D expenses to $1.0 million from $2.0 million, while G&A expenses rose slightly to $1.1 million. Bio-Path highlighted recent corporate milestones, including FDA clearance for two clinical trials: prexigebersen-A for solid tumors and BP1002 for relapsed AML patients. As of September 30, 2021, the company had $26.6 million in cash.
Bio-Path Holdings (NASDAQ: BPTH) will hold a conference call on November 12, 2021, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021. The company is focused on developing its proprietary DNAbilize® antisense RNAi nanoparticle technology to treat cancers. Bio-Path's lead candidate, prexigebersen (BP1001), is in a Phase 2 trial targeting blood cancers. It is also developing BP1002 and BP1003, with an IND filing expected in 2022 for BP1003. Access to the call can be made via phone or through a live webcast on the company’s website.
Bio-Path Holdings (BPTH) announced a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. The presentation will feature safety and preliminary efficacy data from the Phase 2 trial of prexigebersen (BP1001), targeting acute myeloid leukemia. Dr. Maro Ohanian from M.D. Anderson Cancer Center will lead the presentation on December 11, detailing the therapy's safety and efficacy in patients with high-risk and relapsed/refractory AML. This event is pivotal for showcasing BPTH's innovative drug development.
Bio-Path Holdings has received FDA clearance for its IND application to start a Phase 1/1b clinical trial of prexigebersen-A targeting solid tumors, including ovarian and triple negative breast cancer. This marks a significant milestone as the company advances its fourth drug candidate into clinical testing. Preclinical trials showed a promising 86% decrease in tumor burden with no toxicity noted in animal studies. The trial will treat patients using a 3+3 design across multiple cancer centers, beginning with six evaluable patients.
Bio-Path Holdings has received FDA clearance for the IND application of BP1002, its second drug candidate, which aims to treat refractory/relapsed acute myeloid leukemia (AML). This Phase 1/1b clinical trial will evaluate BP1002's efficacy targeting the Bcl-2 protein. The trial is expected to involve several leading cancer centers, starting with six evaluable patients. Preclinical studies suggest BP1002 combined with decitabine may benefit patients resistant to current therapies. The study’s design includes a 3+3 model, with a starting dose of 20 mg/m² administered twice weekly.
Bio-Path Holdings (NASDAQ:BPTH) announced its Q2 2021 financial results, reporting a net loss of $1.8 million or $0.26 per share, an improvement from a loss of $2.0 million in Q2 2020. The company has made strides in advancing its DNAbilize portfolio, notably being granted a new U.S. patent for its BP1003 program. Additionally, cash reserves increased to $28.1 million as of June 30, 2021, compared to $13.8 million at the end of 2020. A conference call is scheduled for today at 8:30 A.M. ET to discuss these developments.
Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced a live conference call scheduled for August 13, 2021, at 8:30 a.m. ET. During this call, the company will report its financial results for Q2 ended June 30, 2021, and discuss its business overview. Bio-Path is focused on developing its DNAbilize® antisense RNAi nanoparticle technology, with its lead candidate, prexigebersen, currently in Phase 2 studies for blood cancers. The company is also preparing for FDA consideration of prexigebersen-A for solid tumors and has ongoing studies for BP1002 in lymphoma.
Bio-Path Holdings (NASDAQ:BPTH) announced the granting of a new patent by the U.S. Patent and Trademark Office for BP1003, an innovative cancer treatment designed to inhibit STAT3 expression. This patent (U.S. Patent No. 11,041,153) reinforces the company's proprietary DNAbilize technology, aimed at enhancing drug delivery for difficult-to-treat cancers like pancreatic cancer and acute myeloid leukemia. The company aims to advance BP1003's development in pancreatic cancer next year.